Revenue (Tables)

9 Months Ended

Sep. 30, 2020

Disaggregation of Revenue [Abstract]

Disaggregation of Revenue [Table Text Block]

The following tables disaggregate our revenue from contracts with customers by business and geographic region (in millions):

	Three Months Ended September 30,
	2020						2019
Businesses	U.S.		OUS		Total		U.S.		OUS		Total
Endoscopy	$	270	$	205	$	475	$	277	$	209	$	486
Urology and Pelvic Health	251		99		350		257		102		359
Cardiac Rhythm Management	275		190		465		284		194		478
Electrophysiology	33		43		76		38		43		81
Neuromodulation	176		41		216		183		39		222
Interventional Cardiology	255		331		586		327		373		700
Peripheral Interventions	236		179		416		195		163		358
Specialty Pharmaceuticals	65		10		74		19		4		23
Net Sales	$	1,560	$	1,098	$	2,659	$	1,580	$	1,126	$	2,707

	Nine Months Ended September 30,
	2020						2019
Businesses	U.S.		OUS		Total		U.S.		OUS		Total
Endoscopy	$	715	$	550	$	1,265	$	800	$	596	$	1,396
Urology and Pelvic Health	650		260		910		737		297		1,033
Cardiac Rhythm Management	738		515		1,253		860		607		1,467
Electrophysiology	86		116		202		113		132		245
Neuromodulation	426		103		529		487		125		612
Interventional Cardiology	741		973		1,714		942		1,126		2,067
Peripheral Interventions	649		499		1,148		507		482		989
Specialty Pharmaceuticals	162		21		183		19		4		23
Net Sales	$	4,167	$	3,037	$	7,204	$	4,462	$	3,369	$	7,831

	Three Months Ended September 30,				Nine Months Ended September 30,
Geographic Regions	2020		2019		2020		2019
U.S.	$	1,496	$	1,561	$	4,005	$	4,443
EMEA (Europe, Middle East and Africa)	540		535		1,507		1,667
APAC (Asia-Pacific)	472		485		1,292		1,403
LACA (Latin America and Canada)	77		102		217		294
Medical Devices	2,584		2,684		7,021		7,807
U.S.	65		19		162		19
OUS	10		4		21		4
Specialty Pharmaceuticals	74		23		183		23
Net Sales	$	2,659	$	2,707	$	7,204	$	7,831
Emerging Markets (1)	$	278	$	310	$	800	$	925

(1)    We define Emerging Markets as the 20 countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities. Periodically, we assess our list of Emerging Markets, which is currently comprised of the following countries: Argentina, Brazil, Chile, China, Colombia, Czech Republic, India, Indonesia, Malaysia, Mexico, Philippines, Poland, Russia, Saudi Arabia, Slovakia, South Africa, South Korea, Thailand, Turkey and Vietnam.